B7-2/CD86 Antibody (1029808) [Alexa Fluor® 488]

• Reactivity: Pm-Cm
• Applications: WB, IHC, KO
• Clone: 1029808
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 488

B7-2/CD86 Antibody (1029808) [Alexa Fluor® 488] Summary

• Immunogen: Human embryonic kidney cell HEK293-derived cynomolgus monkey B7-2/CD86 protein
  Leu20-His239
  Accession # XP_005548057
• Specificity: Detects cynomolgus monkey B7-2/CD86 in direct ELISAs.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry
  • Knockout Validated
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for B7-2/CD86 Antibody (1029808) [Alexa Fluor® 488]

• Activation B7-2 antigen
• B70
• B7-2 antigen
• B72
• B7-2
• B-lymphocyte activation antigen B7-2
• BU63
• CD28 antigen ligand 2
• CD28LG2B7-2 antigen)
• CD86 antigen
• CD86 molecule
• CD86
• CTLA-4 counter-receptor B7.2
• FUN-1
• LAB72
• MGC34413
• T-lymphocyte activation antigen CD86

Background

B7-2, also known as CD86, B70, and ETC-1, is a 60-100 kDa variably glycosylated protein in the B7 family. B7 family members are transmembrane cell surface molecules that play important roles in immune activation and the maintenance of immune tolerance (1, 2). Within the ECD, cynomolgus B7-2 shares 96%, 57%, and 56% amino acid sequence identity with human, mouse and rat B7-2, respectively. B7-2 is highly expressed on activated antigen presenting cells (APC), e.g. B cells, dendritic cells, and monocytes (2-5), as well as on vascular endothelial cells (6). B7-2 and the closely related B7-1/CD80 exhibit overlapping but distinct functional properties. Their binding to CD28, which is constitutively expressed on T cells, enhances T cell receptor signaling and also provides TCR-independent co-stimulation (3, 5, 7-9). B7-1 and B7-2 additionally bind the CD28-related protein, CTLA-4, which is up‑regulated and recruited to the immunological synapse (IS) at the onset of T cell activation (3, 5, 7, 8). CTLA-4 ligation inhibits the T cell response and supports regulatory T cell function (10). B7-2 is expressed earlier than B7-1 following APC activation (4), and both proteins bind with higher affinity to CTLA-4 than to CD28 (8). B7-2 promotes the stabilization of CD28 in the IS, while B7-1 is primarily responsible for promoting CTLA-4 recruitment and accumulation in the IS (11). The relative participation of B7-1 and B7-2 in T cell co-stimulation can also alter the Th1/Th2 bias of the immune response (12). Both B7-1 and B7-2 serve as cellular receptors for B species adenoviruses (13).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.